Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Sep 19, 2022 6:00pm
230 Views
Post# 34972376

RE:Cantor Conference

RE:Cantor ConferenceSome points worth making about this conference. First, the conference will have a lot of cancer specialist portfolio managers at it. It is important for TH to get in front of just this group of analysts and have them become familiar with the stock since that will make it easier for them to buy when and if TH announces good efficacy results. Second, these analysts will actually show up and listen to this panel whereas they likely would not have showed up to a THTX only presentation at a different point in the conference. So, this is pretty ideal from THTX 's perspective. Third, why present at a cancer conference like this if you are soon going to fall flat on your face with TH-1902? TH already has a significant amount of 12 week data so it tells me they are happy with what they are seeing. Fourth, Cantor doesn't put TH on this panel unless they thought theree was a good chance that data was intriguing and that TH would be raising money using Cantor sometime soon. Remember, Cantor is who they set their ATM faciliity up with. Also, it might mean the long awaited Cantor research report might be in progress. 

palinc2000 wrote: Too late for the couple in the midst of a divorce! !!!
Paul should have hired a marriage counsellor to delay the sale of the couples THTX holding
Paul cant do anything right! Lol


<< Previous
Bullboard Posts
Next >>